MassachusettsGeneral Hospital (MGH) doctors are reporting an unanticipated side-effect from treatment with dupilumab, which is FDA authorized for the treatment of moderate to serious eczema, likewise called atopic dermatitis. In their case report released in JAMA Dermatology, the doctors explain how their 13- year-old patient, who has alopecia totalis– an overall absence of scalp hair– along with eczema, experienced substantial hair regrowth while being dealt with with dupilumab, a drug marketed under the trademark name Dupixent.
“We were quite surprised since this patient hadn’t grown scalp hair since the age of 2, and other treatments that can help with hair loss did not in her case,” states Maryanne Makredes Senna, MD, of the MGH Department of Dermatology, senior author of the JAMA Dermatology report. “As far as we know, this is the first report of hair regrowth with dupilumab in a patient with any degree of alopecia areata.”
In addition to longstanding alopecia, this patient had actually experienced substantial, treatment-resistant eczema given that the age of 7 months. Treatment with prednisone and methotrexate, medications that can reduce the overactive body immune system, resulted in minimal enhancement in the patient’s eczema however no hair regrowth and was for that reason terminated. In July 2017 she started to be dealt with with weekly injections of dupilumab, which had actually just recently gotten FDA approval. After 6 weeks of treatment, which resulted in substantial enhancement in eczema signs, she likewise observed that great light hairs called vellus hairs were appearing on her scalp.
After 7 months of dupilumab treatment, the patient had actually grown a considerable quantity of the pigmented hair that normally grows on the scalp. Because of a modification in her insurance protection, she needed to terminate dupilumab for a two-month duration, throughout which she observed shedding of the just recently regrown hair. But after she might resume treatment in April 2018, the hair growth resumed and has actually continued.
Senna discusses that dupilumab’s system of targeting an essential body immune system path understood to be overactive in eczema might describe its action versus alopecia, given that current research studies have actually recommended other components of the exact same path might cause autoimmune loss of hair. “Right now, it’s hard to know whether dupilumab could induce hair growth in other alopecia patients, but I suspect it may be helpful in patients with extensive active eczema and active alopecia areata,” she states. “We’ve submitted a proposal for a clinical trial using dupilumab in this patient population and hope to be able to investigate it further in the near future.” Senna is the primary private investigator of the HairAcademic Innovative Research ( HAIR) medical research study system at MGH and a trainer in Dermatology at Harvard Medical School.
The lead author of the JAMA Dermatology report is Lauren Penzi, MD, a previous research study fellow at MGH Dermatology and now a dermatology citizen at JohnsHopkins Additional co-authors are Mariko Yasuda, MD, Athena Manatis-Lornell and Dina Hagigeorges, all of MGHDermatology No outdoors assistance was gotten for the preparation of this report.
Source: MassachusettsGeneral Hospital